• Publications
  • Influence
Cholinesterase inhibitors for Alzheimer's disease.
  • S. Stahl
  • Medicine
  • Hospital practice
  • 15 November 1998
TLDR
New cholinesterase inhibitors capable of slowing the progression of Alzheimer's disease are being introduced at a rapid pace, but it is necessary to understand that they affect cholinergic activity in other tissues as well as the brain. Expand
Stahl's essential psychopharmacology : neuroscientific basis and practical application
TLDR
The fourth edition CME information about chemical neurotransmission, receptors and enzymes as targets of psychopharmacological drug action, and its implications for treatment of mood disorders, anxiety disorders and anxiolytics is presented. Expand
Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation
TLDR
The rationale for and the design of α 4 β 2 nAChR partial agonists as novel treatments for tobacco addiction are discussed and the clinical efficacy of varenicline, which has significantly better quit rates than do other treatments and offers a new option for smoking cessation pharmacotherapy, is demonstrated. Expand
Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
Preface 1. Principles of chemical neurotransmission 2. Receptors and enzymes as the targets of drug action 3. Special properties of receptors 4. Chemical neurotransmission as the mediator of diseaseExpand
A novel augmentation strategy for treating resistant major depression.
TLDR
Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone. Expand
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
Abstract The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of bothExpand
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.
TLDR
The rationale for and the design of alpha(4)beta(2) nAChR partial agonists as novel treatments for tobacco addiction are discussed and varenicline, which has significantly better quit rates than do other treatments and offers a new option for smoking cessation pharmacotherapy, is demonstrated. Expand
Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects.
  • S. Stahl
  • Medicine, Psychology
  • Journal of affective disorders
  • 1 December 1998
TLDR
The hypothesis to explain why SSRIs have such diverse therapeutic actions is that somatodendritic 5HT1A autoreceptor desensitization increases serotonin in critical brain regions and at those key serotonin receptor subtype(s) which may mediate the pathophysiologies of the various disorders. Expand
A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.
TLDR
The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Expand
The psychopharmacology of energy and fatigue.
  • S. Stahl
  • Medicine, Psychology
  • The Journal of clinical psychiatry
  • 2002
TLDR
Tiredness, low energy, and listlessness are the most common symptoms associated with depression, and recent understanding of interactions between monoaminergic neurons may help explain why some antidepressants may be more rapidly energy restoring than others. Expand
...
1
2
3
4
5
...